HK1206791A1 - Means and methods for response prediction of hepatitis b treatment - Google Patents

Means and methods for response prediction of hepatitis b treatment Download PDF

Info

Publication number
HK1206791A1
HK1206791A1 HK15107184.4A HK15107184A HK1206791A1 HK 1206791 A1 HK1206791 A1 HK 1206791A1 HK 15107184 A HK15107184 A HK 15107184A HK 1206791 A1 HK1206791 A1 HK 1206791A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
treatment
methods
determining whether
response prediction
Prior art date
Application number
HK15107184.4A
Other languages
English (en)
Chinese (zh)
Inventor
Hendrik Willem REESINK
Louis JANSEN
Neeltje Akke KOOTSTRA
Original Assignee
Academisch Medisch Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Medisch Centrum filed Critical Academisch Medisch Centrum
Publication of HK1206791A1 publication Critical patent/HK1206791A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15107184.4A 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment HK1206791A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160199.1 2012-03-19
EP12160199 2012-03-19
EP12186188 2012-09-26
EP12186188.4 2012-09-26
PCT/NL2013/050204 WO2013141705A2 (en) 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment

Publications (1)

Publication Number Publication Date
HK1206791A1 true HK1206791A1 (en) 2016-01-15

Family

ID=47997743

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107184.4A HK1206791A1 (en) 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment

Country Status (9)

Country Link
US (2) US20150044167A1 (enExample)
EP (1) EP2828401B1 (enExample)
BR (1) BR112014023296A2 (enExample)
ES (1) ES2657266T3 (enExample)
HK (1) HK1206791A1 (enExample)
IN (1) IN2014MN01989A (enExample)
MX (1) MX2014011256A (enExample)
RU (1) RU2640256C2 (enExample)
WO (1) WO2013141705A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829548A (zh) * 2013-12-17 2016-08-03 豪夫迈·罗氏有限公司 用于hbv治疗反应的生物标记物
EP3322820A1 (en) * 2015-07-15 2018-05-23 H. Hoffnabb-La Roche Ag Biomarkers for hbv treatment response
CN109504763B (zh) * 2018-12-17 2020-09-04 北京三元基因药业股份有限公司 用于预测α干扰素治疗乙肝患者疗效的分子标记
UA129589C2 (uk) 2018-12-19 2025-06-11 Лео Фарма А/С Аніліди амінокислот як низькомолекулярні модулятори il-17
CN115267193B (zh) * 2022-09-20 2022-12-27 北京大学 用于判断生物样本中HBsAg来源的方法及系统和用途

Also Published As

Publication number Publication date
MX2014011256A (es) 2015-07-14
US20150044167A1 (en) 2015-02-12
IN2014MN01989A (enExample) 2015-07-10
WO2013141705A3 (en) 2013-12-05
BR112014023296A2 (pt) 2019-09-24
US20180044735A1 (en) 2018-02-15
RU2014142009A (ru) 2016-05-10
ES2657266T3 (es) 2018-03-02
EP2828401A2 (en) 2015-01-28
EP2828401B1 (en) 2017-10-25
WO2013141705A2 (en) 2013-09-26
RU2640256C2 (ru) 2017-12-27

Similar Documents

Publication Publication Date Title
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
HK1211260A1 (en) Method and kit for nucleic acid sequencing
ES2935860T5 (en) Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX381592B (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2014145296A3 (en) Nuclei acid amplification
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
WO2013006756A3 (en) Alpha amylase variants and polynucleotides encoding same
WO2013036929A8 (en) Methods for obtaining a sequence
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
WO2012095639A3 (en) Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence
HK1256342A1 (zh) 环境或生物样本中的核酸纯化
WO2013057141A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
WO2013057143A3 (en) Alpha-amylase variants and polynucleotides encoding same
EP3211074A3 (en) Lipase variants and polynucleotides encoding same
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2014195356A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms